Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.30 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7614631 | 0.90 | EPHX2 (0.33) | — | |
| SCHEMBL30972554 | 0.89 | LTA4H (0.38) | LTA4H | |
| SCHEMBL25448646 | 0.86 | PLA2G10 (0.34) | PLA2G10PLA2G5 | |
| SCHEMBL25695967 | 0.86 | PLA2G10 (0.34) | PLA2G10PLA2G5 | |
| SCHEMBL504404 | 0.86 | MGLL (0.33) | — | |
| SCHEMBL504403 | 0.86 | MGLL (0.33) | — | |
| SCHEMBL30662066 | 0.84 | PLK1 (0.32) | PLK1 | |
| SCHEMBL19557850 | 0.82 | MGLL (0.31) | — | |
| SCHEMBL5689117 | 0.80 | ALOX15 (0.43) | — | |
| SCHEMBL28235818 | 0.80 | GRM8 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10413594-B2 | Conjugates of somatostatin analogues | PROLYNX LLC (US) | 2019-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10413594-B2 | Conjugates of somatostatin analogues | SSTR4, SSTR3, SSTR2 | LTA4H 1098/4885PLK1 2664/4885PLA2G10 1326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.